These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 29552327)

  • 21. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis.
    Xu X; Yin S; Guo H; Li M; Qian Z; Tian X; Li T
    Cancer Manag Res; 2019; 11():4119-4128. PubMed ID: 31190984
    [No Abstract]   [Full Text] [Related]  

  • 23. Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer.
    Snyder M; Bottiglieri S; Almhanna K
    Rev Recent Clin Trials; 2018; 13(2):139-149. PubMed ID: 29595113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug?
    Goel G
    Cancer Manag Res; 2018; 10():425-437. PubMed ID: 29563833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
    Sun R; Horiguchi M; Wei LJ
    J Clin Oncol; 2018 May; 36(13):1378-1379. PubMed ID: 29558278
    [No Abstract]   [Full Text] [Related]  

  • 26. Updates on immunotherapy for colorectal cancer.
    Kalyan A; Kircher S; Shah H; Mulcahy M; Benson A
    J Gastrointest Oncol; 2018 Feb; 9(1):160-169. PubMed ID: 29564182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial.
    Fumet JD; Bertaut A; Bengrine L; Lapierre P; Vincent J; Ghiringhelli F; Falvo N
    Oncotarget; 2018 Feb; 9(16):12599-12608. PubMed ID: 29560093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
    Arakawa S; Horiguchi A; Tomishige H; Kawabe N; Nagata H; Ishihara S; Ito M; Asano Y; Ito R; Isetani M; Shimizu K; Kamio K; Kawai T; Yasuoka H; Imaeda Y
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):649-651. PubMed ID: 29650823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
    Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
    Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is High Expression of Claudin-7 in Advanced Colorectal Carcinoma Associated with a Poor Survival Rate? A Comparative Statistical and Artificial Intelligence Study.
    Ianole V; Danciu M; Volovat C; Stefanescu C; Herghelegiu PC; Leon F; Iftene A; Cusmuliuc CG; Toma B; Drug V; Ciobanu Apostol DG
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer.
    Fei Z; Lijuan Y; Xi Y; Wei W; Jing Z; Miao D; Shuwen H
    Gut Pathog; 2019; 11():18. PubMed ID: 31168325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials.
    Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis.
    Zhou M; Yu P; Qu J; Chen Y; Zhou Y; Fu L; Zhang J
    Cell Physiol Biochem; 2016; 40(1-2):361-369. PubMed ID: 27866194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials.
    Jang HJ; Kim BJ; Kim JH; Kim HS
    Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Who will benefit more from maintenance therapy of metastatic colorectal cancer?
    Zhou M; Fu L; Zhang J
    Oncotarget; 2018 Feb; 9(15):12479-12486. PubMed ID: 29552327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is FOLFOXIRI alone or combined with targeted therapy administered as first-line treatment a reasonable choice for most patients with mCRC? Systematic review and network meta-analysis.
    Zhou M; Yu P; Hernick Davin DB; Li Y; Wang Y; Fu L; Zhang J
    Oncotarget; 2017 Sep; 8(37):62339-62348. PubMed ID: 28977949
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.